However, sensitivity to BCL2 inhibition in vitro using ABT199 in a small number of tested patients was high across both CD34+ and CD34- AML blast types with different ROS, ki67 and BCL2 levels. This evidence concerns the gene CD34 and acute myeloid leukemia.